Accolade (NASDAQ:ACCD – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect Accolade to post earnings of ($0.11) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Accolade Stock Performance
Accolade stock opened at $9.21 on Tuesday. The firm has a 50 day simple moving average of $9.97 and a 200-day simple moving average of $9.92. Accolade has a 1-year low of $6.33 and a 1-year high of $17.00. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.35 and a quick ratio of 2.35. The stock has a market cap of $712.95 million, a price-to-earnings ratio of -5.58 and a beta of 2.08.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Raymond James increased their price objective on shares of Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 9th. William Blair reaffirmed an “outperform” rating on shares of Accolade in a research report on Tuesday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price objective on shares of Accolade in a research report on Friday, January 19th. Stifel Nicolaus decreased their price objective on shares of Accolade from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Monday. Finally, Barclays assumed coverage on shares of Accolade in a research report on Wednesday, January 3rd. They issued an “equal weight” rating and a $13.00 price target for the company. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.53.
About Accolade
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
Read More
- Five stocks we like better than Accolade
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How to Calculate Inflation Rate
- Merger or Not, Albertson’s Companies is a Good Buy
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.